drugset / Trial / NCT05428943
OPT101 in Type 1 Diabetes Patients
RandomizedParallel-groupTriple-blindOther
Summary
Phase 1b designed to assess safety, pharmacokinetics, immunological and clinical effects of multiple ascending doses of OPT101.
Timeline
- Start
- 2022-09-27
- Primary completion
- 2024-02-21
- Completion
- 2024-02-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OPT101 | Peptide | 1.1 mg/kg | — |
| Subject | OPT101 | Peptide | 2.8 mg/kg | — |